Back to Search Start Over

Covid-19 and Growth Hormone/Insulin-Like Growth Factor 1: Study in Critically and Non-Critically Ill Patients.

Authors :
Ilias I
Diamantopoulos A
Botoula E
Athanasiou N
Zacharis A
Tsipilis S
Jahaj E
Vassiliou AG
Vassiliadi DA
Kotanidou A
Tsagarakis S
Dimopoulou I
Source :
Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2021 Jun 16; Vol. 12, pp. 644055. Date of Electronic Publication: 2021 Jun 16 (Print Publication: 2021).
Publication Year :
2021

Abstract

Objective: We aimed to measure insulin-like growth factor 1 (IGF1) and growth hormone (GH) in critically and non-critically ill patients with Covid-19 and assess them vis-a-vis clinical and laboratory parameters and prognostic tools.<br />Subjects and Methods: We included patients who were admitted to the wards or the ICU of the largest Covid-19 referral hospital in Greece; patients with non-Covid-19 pneumonia served as controls. Apart from the routine laboratory work-up for Covid-19 we measured GH and IGF1 (and calculated normalized IGF-1 values as standard deviation scores; SDS), after blood sampling upon admission to the wards or the ICU.<br />Results: We studied 209 critically and non-critically ill patients with Covid-19 and 39 control patients. Patients with Covid-19 who were ICU non-survivors were older and presented with a worse hematological/biochemical profile (including white blood cell count, troponin, glucose, aminotransferases and lactate dehydrogenase) compared to ICU survivors or Covid-19 survivors in the wards. Overall, IGF-1 SDS was higher in Covid-19 survivors compared to non-survivors (-0.96 ± 1.89 vs -2.05 ± 2.48, respectively, p=0.030). No significant differences were noted in GH between the groups. Nevertheless, in critically ill patients with Covid-19, the prognostic value of IGF-1 (raw data), IGF-1 (SDS) and GH for survival/non-survival was on a par with that of APACHE II and SOFA (with a marginal difference between GH and SOFA).<br />Conclusion: In conclusion, our findings suggest that there might be an association between low IGF1 (and possibly GH) and poor outcome in patients with Covid-19.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2021 Ilias, Diamantopoulos, Botoula, Athanasiou, Zacharis, Tsipilis, Jahaj, Vassiliou, Vassiliadi, Kotanidou, Tsagarakis and Dimopoulou.)

Details

Language :
English
ISSN :
1664-2392
Volume :
12
Database :
MEDLINE
Journal :
Frontiers in endocrinology
Publication Type :
Academic Journal
Accession number :
34220703
Full Text :
https://doi.org/10.3389/fendo.2021.644055